If changing the antipsychotic drug is not possible, and lifestyle interventions are not effective, adding metformin to the patient’s medications may be helpful in reducing the metabolic effects, but limited data support its efficacy for this off-label indication.13,21, Prolactin levels can also become elevated as a result of treatment with antipsychotic medications. Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Accessed November 24, 2019. Updated January 21, 2020. 1 While some of these therapies may help treat the negative and cognitive symptoms of schizophrenia, a few are associated with QTc interval prolongation. The experimental drug, in contrast, leaves D2 alone. Also, no statistically significant differences in vital signs, weight, metabolic profile, or EPS emerged, compared with placebo. The drug — dubbed SEP-363856 — also appeared to avoid the side effects common with standard antipsychotic medications. Results showed that both the 75-mg and 100-mg once-monthly doses demonstrated statistically significant improvements (P <.0001) compared with placebo injections in the PANSS and CGI at 12 weeks.43 Complete results have not yet been published. The first medications for schizophrenia were discovered serendipitously in the 1950s, with subsequent “me-too” drugs targeting the same limited number of neurotransmitters. Experts were hopeful that the findings, published April 16 in the New England Journal of Medicine, will lead to a new treatment option. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Please click "Next" if you did not attend this session. Author disclosure: Dr Maroney has the following relevant financial relationships with commercial interests to disclose: Authorship information: Concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; supervision. Participants received either SEP-363856 (50 mg/day or 75 mg/day) or placebo. Updated August 29, 2019. 136. Therefore, the antipsychotic is usually chosen based on patient preference, response to past treatment, tolerability, AE profile, presence of comorbid conditions, drug—drug interactions, drug pharmacokinetics, and drug formulation availability and access. Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Transdermal delivery systems may have benefits over other formulations, such as the ability to visually confirm medication adherence and possible improved tolerability. While there is a laundry list of antipsychotic medications for schizophrenia, they are decades old. The researchers found that there’s lower opioid receptor availability in people with schizophrenia, which could lead to new treatment pathways. PANSS Total Score Change from Baseline … Accessed November 24, 2019. About half were randomly assigned to take SEP-363856 capsules once a day, while the rest received placebo capsules. https://doi.org/10.37765/ajmc.2020.43012Introduction, Schizophrenia is a chronic neuropsychiatric disorder affecting an estimated 3.5 million individuals in the United States.1 It is characterized by a combination of positive symptoms (eg, hallucinations, delusions, disorganized thoughts or speech, and bizarre behaviors), negative symptoms (lack of motivation, drive, enjoyment, social interactions), cognitive dysfunction (affecting attention, memory, executive functioning, social interactions), and motor disturbances that can lead to functional impairment and poor health-related quality of life (QOL).2, At present, there is no cure for schizophrenia, and treatment guidelines recommend a combined approach with pharmacologic agents and psychological interventions for first-episode psychosis, acute exacerbations, and prevention of relapse of psychosis.3 Multiple agents are currently available for the treatment of schizophrenia; however, many fall short of their therapeutic goals, as adherence, cognitive dysfunction, negative symptoms, residual positive symptoms, and adverse effects (AEs) remain a challenge for many patients.2. Marlborough, MA, and Paramus, NJ: Sunovion Pharmaceuticals Inc and PsychoGenics Inc; May 10, 2019. news.sunovion.com/press-release/sunovion-and-psychogenics-announce-sep-363856-has-received-fda-breakthrough-therapy. Jarskog LF, Hamer RM, Catellier DJ, et al; METS Investigators. Cat Parasite Gives Clues on New Drug Targets for Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, second edition. -30-25-20-15-10-5. The trial involved 245 schizophrenia patients aged 18 to 40, all in the earlier course of the disease. The primary end point being studied is the change in Negative Symptom Assessment-16 (NSA-16) total score from baseline to week 26.41 Topline results of the study showed a statistically significant improvement in NSA-16 score as compared with placebo (—10.4 vs –8.5; P = .0043).42 Further results have not yet been published. New York, NY: Intra-Cellular Therapies, Inc; 2019. www.intracellulartherapies.com/docs/caplyta_pi.pdf. Share on Facebook. Lumateperone 60 mg/day demonstrated statistically significant superiority in the change in the Positive and Negative Syndrome Scale (PANSS) total score versus placebo, with a least squares mean change from baseline on the PANSS total score of —14.5 points versus –10.3 points with placebo (P = .022). Europe/London . American Journal of Psychiatry. Consensus development conference on antipsychotic drugs and obesity and diabetes. clinicaltrials.gov/ct2/show/NCT02694328. However, a new treatment using the deep brain stimulation technique could improve the condition of patients. News Nov 17, 2020 | Original story from the University of Leeds . McClellan J, Sikich L, Findling RL, et al. Researchers have … She identifies 12 individuals diagnosed with schizophrenia and randomly assigns them to one of three groups: (a) no treatment; (b) psychotherapy; and (c) psychotherapy in conjunction with psychoactive medication.